An improvement to the global software standard for analyzing fusion plasmas
2015-04-24
(Press-News.org) The gold standard for analyzing the behavior of fusion plasmas may have just gotten better. Mario Podestà, a staff physicist at the U.S. Department of Energy's Princeton Plasma Physics Laboratory (PPPL), has updated the worldwide computer program known as TRANSP to better simulate the interaction between energetic particles and instabilities - disturbances in plasma that can halt fusion reactions. The program's updates, reported this week in the journal Nuclear Fusion, could lead to improved capability for predicting the effects of some types of instabilities in future facilities such as ITER, the international experiment under construction in France to demonstrate the feasibility of fusion power.
Podestà and co-authors saw a need for better modeling techniques when they noticed that while TRANSP could accurately simulate an entire plasma discharge, the code wasn't able to represent properly the interaction between energetic particles and instabilities. The reason was that TRANSP, which PPPL developed and has regularly updated, treated all fast-moving particles within the plasma the same way. Those instabilities, however, can affect different parts of the plasma in different ways through so-called "resonant processes."
The authors first figured out how to condense information from other codes that do model the interaction accurately - albeit over short time periods - so that TRANSP could incorporate that information into its simulations. Podestà then teamed up with TRANSP developer Marina Gorelenkova at PPPL to update a TRANSP module called NUBEAM to enable it to make sense of this condensed data. "Once validated, the updated module will provide a better and more accurate way to compute the transport of energetic particles," said Podestà. "Having a more accurate description of the particle interactions with instabilities can improve the fidelity of the program's simulations."
Fast-moving particles, which result from neutral beam injection into tokamak plasmas, cause the instabilities that the updated code models. These particles begin their lives with a neutral charge but turn into negatively charged electrons and positively charged ions - or atomic nuclei - inside the plasma. This scheme is used to heat the plasma and to drive part of the electric current that completes the magnetic field confining the plasma.
The improved simulation tool may have applications for ITER, which will use fusion end-products called alpha particles to sustain high plasma temperatures. But just like the neutral beam particles in current-day-tokamaks, alpha particles could cause instabilities that degrade the yield of fusion reactions. "In present research devices, only very few, if any, alpha particles are generated," said Podestà. "So we have to study and understand the effects of energetic ions from neutral beam injectors as a proxy for what will happen in future fusion reactors."
PPPL, on Princeton University's Forrestal Campus in Plainsboro, N.J., is devoted to creating new knowledge about the physics of plasmas -- ultra-hot, charged gases -- and to developing practical solutions for the creation of fusion energy. Results of PPPL research have ranged from a portable nuclear materials detector for anti-terrorist use to universally employed computer codes for analyzing and predicting the outcome of fusion experiments. The Laboratory is managed by the University for the U.S. Department of Energy's Office of Science, which is the largest single supporter of basic research in the physical sciences in the United States, and is working to address some of the most pressing challenges of our time. For more information, please visit science.energy.gov.
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2015-04-24
Negative feedback can sting, but thinking about the big picture may help transform criticism into positive change, according to new research published by the Society for Personality and Social Psychology.
"People are defensive when they are told about something they did wrong," said lead researcher Jennifer Belding, Ph.D., from Ohio State University. "Listening to negative feedback requires self-control because you have to get past the fact that hearing it hurts and instead use the information to improve over time."
In three experiments, researchers found that ...
2015-04-24
24.4.2015: Gigantic volumes of hot material rising from the deep earth's mantle to the base of the lithosphere have shaped the face of our planet. Provided they have a sufficient volume, they can lead to break-up of continents or cause mass extinction events in certain periods of the Earth's history. So far it was assumed that because of their high temperatures those bodies - called mantle plumes - ascend directly from the bottom of the earth's mantle to the lithosphere. In the most recent volume of Nature Communications, a team of researchers from the Geodynamic Modeling ...
2015-04-24
A new study of the complex interplay between organisms and their environment shows that biodiversity--the variety of organisms living on Earth--is even more important to the healthy functioning of ecosystems than previously thought.
The findings bolster the view that conservation of biodiversity benefits the plants and animals directly involved, and by extension the human populations that rely on these organisms and ecosystems for food, water, and other basic services.
Lead author on the study, to be published in the online journal Nature Communications on April 24, ...
2015-04-24
Philadelphia, April 24, 2015 -- Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naïve patients with cirrhotic or non-cirrhotic chronic hepatitis C virus (HCV) genotype 1, 4, or 6. These findings suggest that once-daily oral grazoprevir/elbasvir represents a new therapeutic option for chronic HCV infection.
Data from the Phase 3 C-EDGE Treatment-Naïve Trial are being presented for the first time at the 50th annual congress of the European ...
2015-04-24
Harvard Stem Cell Institute (HSCI) researchers at Massachusetts General Hospital (MGH) have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival. The study published online in the journal Brain also describes a strategy of preventing the potential negative consequences of stem cell therapy.
"Metastatic brain tumors - often from lung, breast or skin cancers - are the most commonly observed tumors within the brain and account for about ...
2015-04-24
April 24, 2015, Vienna, Austria: Results presented today at The International Liver Congress™ 2015 show that a 12-week oral regimen of once-daily single tablet grazoprevir/elbasvir (GZR/EBR) is effective and well-tolerated in treatment-naive (TN) patients infected with chronic hepatitis C virus (HCV) genotypes (GT)-1, -4 or -6, including those with compensated cirrhosis.
Based on preliminary results from 316 GZR/EBR recipients in the immediate treatment arm, 299 patients (95%) achieved a sustained virologic response at 12 weeks (SVR12).
"These initial results ...
2015-04-24
April 24, 2015, Vienna, Austria: A new study presented today at The International Liver Congress™ 2015 has demonstrated that ledipasvir (LDV) in combination with sofosbuvir (SOF) achieves sustained virologic response rates 12 weeks after treatment (SVR12; primary endpoint), of 93% and 95% in patients chronically infected with hepatitis C virus (HCV) genotypes 4 or 5, respectively.
In the study, LDV/SOF was administered in a once-daily, fixed-dose combination tablet for 12 weeks to treatment-naive and treatment-experienced patients with or without cirrhosis. A total ...
2015-04-24
April 24, 2015, Vienna , Austria: Results announced today at The International Liver CongressTM 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.
The aim of the study was to describe the rates of all cancers in the cohort of HCV patients compared to the non-HCV population. Known cancer types associated with hepatitis C include non-Hodgkin's lymphoma, renal and prostate cancers, as well as liver ...
2015-04-24
April 24, 2015, Vienna, Austria: Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway. BLU-554, a small molecule inhibitor of FGFR4, has been identified as a potential treatment option for up to 30% of HCC patients. In preclinical studies, the investigational drug was shown to be potent and 'exquisitely selective' for FGFR4 compared to other kinases targeting the FGFR family. ...
2015-04-24
April 24, 2015, Vienna, Austria: Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).
Reported today at The International Liver CongressTM 2015, the large study analysed the overall burden of cardiovascular disease and all-cause mortality across the spectrum of NAFLD. The four stages of NAFLD are steatosis (or simple fatty liver), non-alcoholic steatohepatitis ...
LAST 30 PRESS RELEASES:
[Press-News.org] An improvement to the global software standard for analyzing fusion plasmas